Feeling a little overwhelmed at all the things I need to be good at—diagnostic bronchs and lung cancer, other therapeutic pulm procedures, MICU, cardiac crit care, neuroICU, MCS, PH, complex ILD, CPETs, neuromusc resp failure, CF, pleural disease…3 years out of training and feel like I can’t keep up
October 30, 2025 at 12:30 PM
Feeling a little overwhelmed at all the things I need to be good at—diagnostic bronchs and lung cancer, other therapeutic pulm procedures, MICU, cardiac crit care, neuroICU, MCS, PH, complex ILD, CPETs, neuromusc resp failure, CF, pleural disease…3 years out of training and feel like I can’t keep up
3/DESTINY-Breast12
📊Ph 3b/4 trial of T-DXd in HER2+ mBC w/ or w/o brain mets(BM)
🧠n=263 pts w/ BM & n=241 pts w/o BM
➡️62% PFS & 59% CNS PFS @ 12mo for pts w/ BM
📈ORR 63% in pts w/o BM
🫁ILD 16% w/ BM & 13% w/o BM
🙌 Substantial, durable intracranial and overall activity
📊Ph 3b/4 trial of T-DXd in HER2+ mBC w/ or w/o brain mets(BM)
🧠n=263 pts w/ BM & n=241 pts w/o BM
➡️62% PFS & 59% CNS PFS @ 12mo for pts w/ BM
📈ORR 63% in pts w/o BM
🫁ILD 16% w/ BM & 13% w/o BM
🙌 Substantial, durable intracranial and overall activity
February 28, 2025 at 5:36 PM
3/DESTINY-Breast12
📊Ph 3b/4 trial of T-DXd in HER2+ mBC w/ or w/o brain mets(BM)
🧠n=263 pts w/ BM & n=241 pts w/o BM
➡️62% PFS & 59% CNS PFS @ 12mo for pts w/ BM
📈ORR 63% in pts w/o BM
🫁ILD 16% w/ BM & 13% w/o BM
🙌 Substantial, durable intracranial and overall activity
📊Ph 3b/4 trial of T-DXd in HER2+ mBC w/ or w/o brain mets(BM)
🧠n=263 pts w/ BM & n=241 pts w/o BM
➡️62% PFS & 59% CNS PFS @ 12mo for pts w/ BM
📈ORR 63% in pts w/o BM
🫁ILD 16% w/ BM & 13% w/o BM
🙌 Substantial, durable intracranial and overall activity
The Bridging Specialties®: Timely Diagnosis for PH-ILD program encourages team-based care in PH-ILD.
🔗 Find out more in CHEST Physician: www.chestphysician.org/newest-bridg...
#MedSky #LungDisease
🔗 Find out more in CHEST Physician: www.chestphysician.org/newest-bridg...
#MedSky #LungDisease
June 26, 2025 at 5:45 PM
The Bridging Specialties®: Timely Diagnosis for PH-ILD program encourages team-based care in PH-ILD.
🔗 Find out more in CHEST Physician: www.chestphysician.org/newest-bridg...
#MedSky #LungDisease
🔗 Find out more in CHEST Physician: www.chestphysician.org/newest-bridg...
#MedSky #LungDisease
The Future of Pulmonary Hypertension Treatment. Dr. Rajan Saggar on the latest advancements in PH-ILD, from new medications to upcoming clinical trials. @phaware.bsky.social podcast ep 515 #phawareMD #PHILD @gossamerbio.bsky.social #Pulmovant #PROSERAstudy #PHOCUSstudy medium.com/p/im-aware-t...
I’m Aware That I’m Rare: Rajan Saggar, MD (515)
the phaware® interview
medium.com
April 7, 2025 at 2:48 PM
The Future of Pulmonary Hypertension Treatment. Dr. Rajan Saggar on the latest advancements in PH-ILD, from new medications to upcoming clinical trials. @phaware.bsky.social podcast ep 515 #phawareMD #PHILD @gossamerbio.bsky.social #Pulmovant #PROSERAstudy #PHOCUSstudy medium.com/p/im-aware-t...
No rheumatologists. Mostly ILD chest, rads, pathologists, plus patient representation. But there were no thoracic surgeons, PH experts, occ med, transplant docs, pall care etc either. and they are all deeply connected to ILD clinical care.
August 17, 2025 at 8:59 PM
No rheumatologists. Mostly ILD chest, rads, pathologists, plus patient representation. But there were no thoracic surgeons, PH experts, occ med, transplant docs, pall care etc either. and they are all deeply connected to ILD clinical care.
Brilliant 2 days at MILD|25 course with excellent organisation, speakers & talks on ILD, HRCT, PPF, HP, OLD, PH, transplant, MDT, myositis, SARD-ILD, CLD, sarcoid, genetics, exacerbations, ILAs & the horizon. Thanks for the invitation to speak to pharmacological considerations in ILD!
March 14, 2025 at 2:15 PM
Brilliant 2 days at MILD|25 course with excellent organisation, speakers & talks on ILD, HRCT, PPF, HP, OLD, PH, transplant, MDT, myositis, SARD-ILD, CLD, sarcoid, genetics, exacerbations, ILAs & the horizon. Thanks for the invitation to speak to pharmacological considerations in ILD!
Ioana Preston, MD explores the emerging field of pulmonary hypertension associated with interstitial lung disease (PH-ILD), highlighting the importance of early screening and diagnosis. @phaware.bsky.social podcast ep 518 #phawareMD #PHILD
@Liquidia_Corp @LaheyHospital medium.com/p/im-aware-t...
@Liquidia_Corp @LaheyHospital medium.com/p/im-aware-t...
I’m Aware That I’m Rare: Ioana Preston, MD (518)
the phaware® interview
medium.com
April 28, 2025 at 11:18 AM
Ioana Preston, MD explores the emerging field of pulmonary hypertension associated with interstitial lung disease (PH-ILD), highlighting the importance of early screening and diagnosis. @phaware.bsky.social podcast ep 518 #phawareMD #PHILD
@Liquidia_Corp @LaheyHospital medium.com/p/im-aware-t...
@Liquidia_Corp @LaheyHospital medium.com/p/im-aware-t...
Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update
https://www.byteseu.com/1262246/
– Topline Results from PROSERA Phase 3 Expected in February 2026 – – First Site Activations for Planned Registrational Phase 3 SERANATA Study in PH-ILD Expected in the …
https://www.byteseu.com/1262246/
– Topline Results from PROSERA Phase 3 Expected in February 2026 – – First Site Activations for Planned Registrational Phase 3 SERANATA Study in PH-ILD Expected in the …
Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update - Bytes Europe
SAN DIEGO--(BUSINESS WIRE)--$GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and
www.byteseu.com
August 6, 2025 at 3:26 PM
Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update
https://www.byteseu.com/1262246/
– Topline Results from PROSERA Phase 3 Expected in February 2026 – – First Site Activations for Planned Registrational Phase 3 SERANATA Study in PH-ILD Expected in the …
https://www.byteseu.com/1262246/
– Topline Results from PROSERA Phase 3 Expected in February 2026 – – First Site Activations for Planned Registrational Phase 3 SERANATA Study in PH-ILD Expected in the …
Key point: Any degree of PH in patients with ILD is associated with increased mortality. BUT, echos are accurate in finding PH in these patients less than 50% of the time! AND we have a therapy for these patients (inhaled treprostinil)! Moral of the story, get the right heart cath
March 1, 2025 at 2:41 PM
Key point: Any degree of PH in patients with ILD is associated with increased mortality. BUT, echos are accurate in finding PH in these patients less than 50% of the time! AND we have a therapy for these patients (inhaled treprostinil)! Moral of the story, get the right heart cath
🔴 #ERSCongress - épidémiologie de la #PID associée à l’hypertension pulmonaire #HTP, #ILD-PH dans le système de santé français #SNDS par le Pr Olivier Sitbon #PulmoTension @hopitalbicetre.bsky.social, Pr Vincent Cottin #OrphaLung @hcl-recherche.bsky.social, N. Petrica, data scientist et D. Funes.
September 28, 2025 at 3:43 PM
🔴 #ERSCongress - épidémiologie de la #PID associée à l’hypertension pulmonaire #HTP, #ILD-PH dans le système de santé français #SNDS par le Pr Olivier Sitbon #PulmoTension @hopitalbicetre.bsky.social, Pr Vincent Cottin #OrphaLung @hcl-recherche.bsky.social, N. Petrica, data scientist et D. Funes.
Now: potential new tx for #PAH and inoperable #CTEPH: “ATMOS, A Proof-of-Concept Trial of Inhaled Mosliciguat, A First-in-Class Soluble Guanylate Cyclase Activator - A Novel Approach to Address Unmet Needs in PH” #DrHosseinGhofrani
Phase II for PH-ILD enrolling now!
Phase II for PH-ILD enrolling now!
May 19, 2025 at 10:09 PM
Now: potential new tx for #PAH and inoperable #CTEPH: “ATMOS, A Proof-of-Concept Trial of Inhaled Mosliciguat, A First-in-Class Soluble Guanylate Cyclase Activator - A Novel Approach to Address Unmet Needs in PH” #DrHosseinGhofrani
Phase II for PH-ILD enrolling now!
Phase II for PH-ILD enrolling now!
We also talked about group 3 PH with Dr Shlobin Oksana. The different pathophysiology of it and possible treatment options.
Differentiate between:
🟢COPD-PH
🟢CPFE-PH
🟢ILD-PH
More studies are needed with better characterisation of PFTs for therapeutic target.
Differentiate between:
🟢COPD-PH
🟢CPFE-PH
🟢ILD-PH
More studies are needed with better characterisation of PFTs for therapeutic target.
April 27, 2025 at 8:39 PM
We also talked about group 3 PH with Dr Shlobin Oksana. The different pathophysiology of it and possible treatment options.
Differentiate between:
🟢COPD-PH
🟢CPFE-PH
🟢ILD-PH
More studies are needed with better characterisation of PFTs for therapeutic target.
Differentiate between:
🟢COPD-PH
🟢CPFE-PH
🟢ILD-PH
More studies are needed with better characterisation of PFTs for therapeutic target.
The study found that patients with severe ILD-PH, particularly those with idiopathic pulmonary fibrosis (IPF), had the poorest prognosis.
October 17, 2025 at 5:32 AM
The study found that patients with severe ILD-PH, particularly those with idiopathic pulmonary fibrosis (IPF), had the poorest prognosis.
September is Interstitial Lung Disease Awareness Month.
To help raise #awareness, Keisha Jackson, an advocate and patient living with four chronic illnesses, including #PH and #ILD, shares her diagnosis story.
Learn more: buff.ly/EJcmneh
To help raise #awareness, Keisha Jackson, an advocate and patient living with four chronic illnesses, including #PH and #ILD, shares her diagnosis story.
Learn more: buff.ly/EJcmneh
September 24, 2025 at 2:05 PM
September is Interstitial Lung Disease Awareness Month.
To help raise #awareness, Keisha Jackson, an advocate and patient living with four chronic illnesses, including #PH and #ILD, shares her diagnosis story.
Learn more: buff.ly/EJcmneh
To help raise #awareness, Keisha Jackson, an advocate and patient living with four chronic illnesses, including #PH and #ILD, shares her diagnosis story.
Learn more: buff.ly/EJcmneh
Dr. Raj Parikh discusses the development of a PH-ILD Detection tool. Early detection is critical, as there's often a significant delay in diagnosis of PH in ILD patients. @phaware.bsky.social podcast ep 517 @HartfordHealthCare @Liquidia_Corp @teamphhope.bsky.social #PHILD medium.com/p/im-aware-t...
I’m Aware That I’m Rare: Raj Parikh, MD (517)
the phaware® interview
medium.com
April 21, 2025 at 3:24 PM
Dr. Raj Parikh discusses the development of a PH-ILD Detection tool. Early detection is critical, as there's often a significant delay in diagnosis of PH in ILD patients. @phaware.bsky.social podcast ep 517 @HartfordHealthCare @Liquidia_Corp @teamphhope.bsky.social #PHILD medium.com/p/im-aware-t...
Foresee Pharmaceuticals Commences Groundbreaking Phase 2 Study for Mirivadelgat in Treating Pulmonary Hypertension-Associated ILD#Taipei#United_States#Foresee_Pharmaceuticals#Mirivadelgat#PH-ILD
Foresee Pharmaceuticals Commences Groundbreaking Phase 2 Study for Mirivadelgat in Treating Pulmonary Hypertension-Associated ILD
Foresee Pharmaceuticals has initiated the Phase 2 WINDWARD study for Mirivadelgat, a promising treatment for patients suffering from PH-ILD. This innovative trial aims to evaluate the drug's safety and effectiveness.
third-news.com
May 15, 2025 at 5:50 AM
Foresee Pharmaceuticals Commences Groundbreaking Phase 2 Study for Mirivadelgat in Treating Pulmonary Hypertension-Associated ILD#Taipei#United_States#Foresee_Pharmaceuticals#Mirivadelgat#PH-ILD
Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD
https://www.europesays.com/uk/153374/
Liquidia Technologies, Inc. YUTREPIA now available to be prescribed to patients via specialty pharmacies FDA …#uk #news #uknews
https://www.europesays.com/uk/153374/
Liquidia Technologies, Inc. YUTREPIA now available to be prescribed to patients via specialty pharmacies FDA …#uk #news #uknews
Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD - United Kingdom
Liquidia Technologies, Inc.
www.europesays.com
June 3, 2025 at 12:18 AM
Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD
https://www.europesays.com/uk/153374/
Liquidia Technologies, Inc. YUTREPIA now available to be prescribed to patients via specialty pharmacies FDA …#uk #news #uknews
https://www.europesays.com/uk/153374/
Liquidia Technologies, Inc. YUTREPIA now available to be prescribed to patients via specialty pharmacies FDA …#uk #news #uknews
#LQDA Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD
https://www.stocktitan.net/news/LQDA/liquidia-schedules-first-commercial-shipment-of-yutrepiatm-5qd4rgydi1or.html
https://www.stocktitan.net/news/LQDA/liquidia-schedules-first-commercial-shipment-of-yutrepiatm-5qd4rgydi1or.html
Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD
Liquidia Corporation announced its first commercial shipment of YUTREPIA (treprostinil) inhalation powder, following FDA approval on May 23, 2025. The drug is now available for prescription through specialty pharmacies for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company achieved rapid market deployment within five business days of approval, including sales force mobilization and compendia listing. Notably, United Therapeutics' attempt to block YUTREPIA's launch through a preliminary injunction and temporary restraining order was denied by the U.S. District Court, which concluded UTHR was unlikely to succeed in their patent infringement claims regarding U.S. Patent No. 11,357,782.
www.stocktitan.net
June 2, 2025 at 10:30 AM
#LQDA Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD
https://www.stocktitan.net/news/LQDA/liquidia-schedules-first-commercial-shipment-of-yutrepiatm-5qd4rgydi1or.html
https://www.stocktitan.net/news/LQDA/liquidia-schedules-first-commercial-shipment-of-yutrepiatm-5qd4rgydi1or.html
Dr. Sarah Khan challenging the status quo definition of “pulmonary vascular phenotype” with a CT-phenotyping methodology in CTD ILD-PH. Amazing work that will help push our field forward! 🤩 #HopkinsPCCM
May 21, 2025 at 4:43 PM
Dr. Sarah Khan challenging the status quo definition of “pulmonary vascular phenotype” with a CT-phenotyping methodology in CTD ILD-PH. Amazing work that will help push our field forward! 🤩 #HopkinsPCCM
Nurse Practitioners, Jennifer Keeley and Mary Whittenhall, discuss the management of cough in patients receiving inhaled therapies for PH and ILD. @phaware.bsky.social podcast ep 550 @gossamerbio.bsky.social #phild #cough #pah @teamphhope.bsky.social #GossamerBioPartner medium.com/p/im-aware-t...
I’m Aware That I’m Rare: Jennifer Keeley, DPN and Mary Whittenhall, MSN (550)
the phaware® interview
medium.com
December 9, 2025 at 3:21 PM
Nurse Practitioners, Jennifer Keeley and Mary Whittenhall, discuss the management of cough in patients receiving inhaled therapies for PH and ILD. @phaware.bsky.social podcast ep 550 @gossamerbio.bsky.social #phild #cough #pah @teamphhope.bsky.social #GossamerBioPartner medium.com/p/im-aware-t...
#中央社即時新聞 財經新聞 19:52
國邑肺高壓新藥三期啟動 同步展開商業化前準備
（中央社記者何秀玲台北8日電）新藥公司國邑今天宣布，已完成首批L606用於PH-ILD（間質性肺病引起的肺高壓）全球第三期臨床試驗的藥品出貨，供應授權夥伴Liquidia啟動國際多中心試驗，預計在明年起啟動全球病患收案，為商業化發展奠定重要里程碑。
https://www.cna.com.tw/news/afe/202512080277.aspx
#新聞
國邑肺高壓新藥三期啟動 同步展開商業化前準備
（中央社記者何秀玲台北8日電）新藥公司國邑今天宣布，已完成首批L606用於PH-ILD（間質性肺病引起的肺高壓）全球第三期臨床試驗的藥品出貨，供應授權夥伴Liquidia啟動國際多中心試驗，預計在明年起啟動全球病患收案，為商業化發展奠定重要里程碑。
https://www.cna.com.tw/news/afe/202512080277.aspx
#新聞
國邑肺高壓新藥三期啟動 同步展開商業化前準備 | 產經 | 中央社 CNA
新藥公司國邑今天宣布，已完成首批L606用於PH-ILD（間質性肺病引起的肺高壓）全球第三期臨床試驗的藥品出貨，供應授權夥伴Liquidia啟動國際多中心試驗，預計在明年起啟動全球病患收案，為商業化發展奠定重要里程碑。
www.cna.com.tw
December 8, 2025 at 1:12 PM
#中央社即時新聞 財經新聞 19:52
國邑肺高壓新藥三期啟動 同步展開商業化前準備
（中央社記者何秀玲台北8日電）新藥公司國邑今天宣布，已完成首批L606用於PH-ILD（間質性肺病引起的肺高壓）全球第三期臨床試驗的藥品出貨，供應授權夥伴Liquidia啟動國際多中心試驗，預計在明年起啟動全球病患收案，為商業化發展奠定重要里程碑。
https://www.cna.com.tw/news/afe/202512080277.aspx
#新聞
國邑肺高壓新藥三期啟動 同步展開商業化前準備
（中央社記者何秀玲台北8日電）新藥公司國邑今天宣布，已完成首批L606用於PH-ILD（間質性肺病引起的肺高壓）全球第三期臨床試驗的藥品出貨，供應授權夥伴Liquidia啟動國際多中心試驗，預計在明年起啟動全球病患收案，為商業化發展奠定重要里程碑。
https://www.cna.com.tw/news/afe/202512080277.aspx
#新聞
Dr. Rodolfo Estrada discusses the technology and clinical development behind YUTREPIA™ (treprostinil) inhalation powder and why it might be a good option for some PAH and PH-ILD patients. @phaware.bsky.social re podcast ep 523 @Liquidia_Corp @uthealthsa.bsky.social medium.com/p/im-aware-t...
I’m Aware That I’m Rare: Rodolfo A Estrada, MD (523)
the phaware® interview
medium.com
June 3, 2025 at 1:45 PM
Dr. Rodolfo Estrada discusses the technology and clinical development behind YUTREPIA™ (treprostinil) inhalation powder and why it might be a good option for some PAH and PH-ILD patients. @phaware.bsky.social re podcast ep 523 @Liquidia_Corp @uthealthsa.bsky.social medium.com/p/im-aware-t...
ERJ: Acute administration of inhaled treprostinil in ILD-PH improves exercise cardiac output reserve, but this occurs at the expense of modest worsening of physiological shunting, pulmonary venous hypertension and arterial hypoxaemia during exercise https://bit.ly/4n0dfym
December 10, 2025 at 3:48 PM
ERJ: Acute administration of inhaled treprostinil in ILD-PH improves exercise cardiac output reserve, but this occurs at the expense of modest worsening of physiological shunting, pulmonary venous hypertension and arterial hypoxaemia during exercise https://bit.ly/4n0dfym
phaware® Launches Special Series of Podcast Episodes Spotlighting the Future of PH-ILD Treatment and Innovation prn.to/3FSuRMD @GossamerBio @Liquidia_Corp #Pulmovant #PHILD
phaware® Launches Special Series of Podcast Episodes Spotlighting the Future of PH-ILD Treatment and Innovation
/PRNewswire/ -- phaware® global association is set to launch an exclusive series of special edition episodes of its acclaimed "I'm Aware That I'm Rare: the...
prn.to
April 1, 2025 at 3:16 PM
phaware® Launches Special Series of Podcast Episodes Spotlighting the Future of PH-ILD Treatment and Innovation prn.to/3FSuRMD @GossamerBio @Liquidia_Corp #Pulmovant #PHILD
The findings suggest that PDE5i therapy could be a valuable intervention for managing severe ILD-PH, though further controlled trials are needed to validate these results.
October 17, 2025 at 5:32 AM
The findings suggest that PDE5i therapy could be a valuable intervention for managing severe ILD-PH, though further controlled trials are needed to validate these results.